One of the strategies of tumor immunotherapy is to specifically target tumor cells rather than normal cells. Chimeric antigen receptor T (CAR-T) cell immunotherapy is a new type of precision-targeted therapy for the treatment of cancer. CAR-T cells efficiently kill tumor cells by specifically binding tumor cell surface antigens through their surface CAR molecules. These tumor cell surface antigens mainly include two types, one is the tumor-specific antigen and the other is the tumor-associated antigen. Currently, in hematological malignancies, CAR-T therapies that target CD19 or BCMA have made remarkable achievements. However, in solid tumors, especially those with low tumor mutation burden, there is a lack of new targets for CAR-T therapy with good specificity and immunogenicity. Currently, many problems need to be solved urgently. For example, more investigations are still needed in the following areas: (1) how to improve the treatment strategy of classical targets CAR-T immunotherapy tolerant patients, (2) how to further treat patients who relapse after classical targets CAR-T therapy, (3) how to avoid the side effects of classical targets CAR-T immunotherapy, and (4) how to treat solid tumors with low tumor mutation burden by CAR-T therapy.
The Research Topic seeks to promote the academic exchange and experience sharing of new targets for CAR-T therapy in cancer. The first aim is to discuss the current situation, existing problems, and development trend of the CAR-T therapy targets. Secondly, we would like to invite our colleagues to contribute some guiding information for the strategy of new target screening for CAR-T therapy in cancer. Finally, the Research Topic aims to provide a platform for the exploration of the new targets for CAR-T therapy, verification of security, prediction of efficacy, and the improvement of treatment strategies.
We welcome the submission of Original Research and Review articles including the following subtopics:
1) Screening of new targets for CAR-T immunotherapy in cancer;
2) Verification of the security and efficacy of CAR-T immunotherapy targeting new targets;
3) Construction of a prediction method for the immunotherapeutic efficacy or prognosis;
4) Evaluation of immune microenvironment of cancer;
5) Other studies related to CAR-T immunotherapy in cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
One of the strategies of tumor immunotherapy is to specifically target tumor cells rather than normal cells. Chimeric antigen receptor T (CAR-T) cell immunotherapy is a new type of precision-targeted therapy for the treatment of cancer. CAR-T cells efficiently kill tumor cells by specifically binding tumor cell surface antigens through their surface CAR molecules. These tumor cell surface antigens mainly include two types, one is the tumor-specific antigen and the other is the tumor-associated antigen. Currently, in hematological malignancies, CAR-T therapies that target CD19 or BCMA have made remarkable achievements. However, in solid tumors, especially those with low tumor mutation burden, there is a lack of new targets for CAR-T therapy with good specificity and immunogenicity. Currently, many problems need to be solved urgently. For example, more investigations are still needed in the following areas: (1) how to improve the treatment strategy of classical targets CAR-T immunotherapy tolerant patients, (2) how to further treat patients who relapse after classical targets CAR-T therapy, (3) how to avoid the side effects of classical targets CAR-T immunotherapy, and (4) how to treat solid tumors with low tumor mutation burden by CAR-T therapy.
The Research Topic seeks to promote the academic exchange and experience sharing of new targets for CAR-T therapy in cancer. The first aim is to discuss the current situation, existing problems, and development trend of the CAR-T therapy targets. Secondly, we would like to invite our colleagues to contribute some guiding information for the strategy of new target screening for CAR-T therapy in cancer. Finally, the Research Topic aims to provide a platform for the exploration of the new targets for CAR-T therapy, verification of security, prediction of efficacy, and the improvement of treatment strategies.
We welcome the submission of Original Research and Review articles including the following subtopics:
1) Screening of new targets for CAR-T immunotherapy in cancer;
2) Verification of the security and efficacy of CAR-T immunotherapy targeting new targets;
3) Construction of a prediction method for the immunotherapeutic efficacy or prognosis;
4) Evaluation of immune microenvironment of cancer;
5) Other studies related to CAR-T immunotherapy in cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
